BRAF Targeted Therapy for Patients with Melanoma and Active Brain Metastases: A Review of Clinical Effectiveness


( Last Updated : October 18, 2017)
Project Line:
Health Technology Review
Project Sub Line:
Summary with Critical Appraisal
Project Number:
RC0936-000

Details


Question


  1. What is the clinical effectiveness of dabrafenib and trametinib for patients with BRAF mutation positive metastatic melanoma with active or symptomatic brain metastasis?

  2. What is the clinical effectiveness of cobimetinib and vemurafenib for patients with BRAF mutation positive metastatic melanoma with active or symptomatic brain metastasis?


Key Message

Data from a non-randomized, no control, open-label phase 2 study suggested that the clinical benefit and tolerability of dabrafenib plus trametinib, as measured by intracranial response and adverse event rate, were found in patients with melanoma and active brain metastasis with BRAF V600E mutation after a median 8.5 months follow-up.